Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial -

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet HIV
Specialities: Infection and infectious diseases
Summary
This Phase 2 RCT (n=125) found that after 24 weeks, bictegravir plus emtricitabine and tenofovir alafenamide (F/TAF) provided similar proportion of patients with HIV RNA load of <50 copies/ml to dolutegravir plus F/TAF (96.9% vs 93.9%).
UKMi comment
Bictegravir is a HIV-1 integrase inhibitor currently under investigation for use in the treatment of HIV.
Related links: